Please login to the form below

Not currently logged in
Email:
Password:

safety review

This page shows the latest safety review news and features for those working in and with pharma, biotech and healthcare.

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo

Until then, Lartruvo will be subject to an annual safety review by the CHMP.

Latest news

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    alone. The conditional approval in the EU means that until the outcome of the ongoing phase III ANNOUNCE trial is known the drug will undergo an annual safety and efficacy review. ... Olaratumab is also under regulatory review in the US and the FDA has

  • Gilead's Zydelig passes EMA safety review Gilead's Zydelig passes EMA safety review

    Gilead's Zydelig passes EMA safety review. Risk of ‘ serious infections’ outweighed by cancer drug’ s benefits. ... The EMA review came after reports from three trials among patients who received either Zydelig or placebo in addition to other

  • Updated EMPA-REG data show Jardiance also protects kidney Updated EMPA-REG data show Jardiance also protects kidney

    The decision was taken in the wake of a safety review by the FDA, which kicked off in May.

  • Study clears Pfizer’s Champix of serious risks Study clears Pfizer’s Champix of serious risks

    Regulators such as the Food and Drug Administration (FDA) should review their safety warning in relation to Champix as this may be unnecessarily limiting access to this effecting smoking cessation aid.”. ... The results come as good news for Pfizer,

  • Nothing but a shell game Nothing but a shell game

    This is the official label and has been vetted by regulators after a careful review of the safety and efficacy data provided by the manufacturer. ... And imagine further that clinicians see value in using this drug for their patients who have

More from news
Approximately 2 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    As AZ can attest, with Forxiga initially being turned down by the FDA and Onglyza under safety review to investigate any link to heart failure, the regulatory environment has been a ... tough one for oral diabetes drugs in recent years, with the FDA

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics